Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Germany / NCT05501379
Recruiting Observational

Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker

NCT05501379 · tracked via the Priya Life Science Germany tracker
Sponsor
University Medicine Greifswald
Phase
Observational
Started
2022-09-21
Last updated
2024-12-27

Condition(s) studied

LymphomaPancreas CancerColorectal Cancer

Investigational drug(s) / intervention(s)

No intervention - observational study only

No intervention - observational study only: No intervention - observational study only

Study summary

Physical activity is an important aspect of cancer therapy but correct measurement of physical activity is difficult. In this study, the physical activity of patients undergoing cancer therapy is assessed by questionnaire and by motion tracker. The results are then compared to answer whether there are differences between the two measurements. Findings of this study will help to improve the assessment of physical activity in cancer patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * verified diagnosis of lymphoma, colorectal or pancreatic cancer * requirement of surgical, chemo or radio therapy * provision of informed consent Exclusion Criteria: * pregnancy * inability to provide consent * use of a rollator

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University Medicine Greifswald Greifswald Germany Recruiting

More University Medicine Greifswald trials in Germany

A Comparison of Fisetin Kinetics in Young and Old Adults Recruiting
Evaluation of Solanidine as an Exogenous Biomarker to Phenotype CYP2D6 Activity in Humans Starting soon
Acceptance of Mandibular Advancement Devices Enrolling by invitation
Acupuncture for Pain Control After Ambulatory Knee Arthroscopy Recruiting
Prognostic Value of Different Nutritional Screening Tools in Acute Pancreatitis Active, not recruiting

Other trials for the same condition

RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease Active, not recruiting
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer Active, not recruiting
Assessing Pancreatic Fistula Rates After Distal Pancreatectomy Using AEON Endostapler Recruiting
Predicting Cancer Risk With Digital and Molecular Markers Recruiting
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05501379 on ClinicalTrials.gov ↗ ← All trials in Germany